BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Versartis, Inc.  

275 Shorline Drive
Suite 450
Redwood City  California  94065  U.S.A.
Phone: 650-963-8588 Fax: n/a


SEARCH JOBS




Industry
Biotechnology

Segment
Start Up





 Company News
Versartis, Inc. (VSAR) Announces Closing Of Its Initial Public Offering And Full Exercise Of Over-Allottment Option 3/27/2014 9:28:26 AM    More...
Redwood City Biopharma, Versartis, Inc. (VSAR), Hits High End With $126 Million IPO 3/21/2014 7:13:53 AM    More...
Tall Order: Growth Hormone Developer Versartis, Inc. Seeks $80 Million IPO 2/19/2014 7:42:11 AM    More...
Bay Area's Versartis, Inc. Secures $55 Million Series E Financing 2/18/2014 7:20:10 AM    More...
Versartis, Inc. Names Jay Shepard As Executive Chairman Of The Board 1/8/2014 10:09:37 AM    More...
US FDA Grants Orphan Drug Designation To Versartis, Inc.' Treatment For Growth Hormone Deficiency 12/18/2013 10:15:27 AM    More...
Versartis, Inc. Appoints Joshua T. Brumm As Chief Financial Officer 12/16/2013 9:51:30 AM    More...
Versartis, Inc. Closes $20 Million Series D Venture Financing 10/8/2013 6:36:31 AM    More...
Versartis, Inc. Presents Latest Positive Results From Its Pediatric Study of Long-Acting Growth Hormone Treatment at International Endocrinology Conference 9/23/2013 6:41:14 AM    More...
Versartis, Inc. Receives Orphan Drug Status for Its Novel Long-Acting Growth Hormone Treatment From European Commission (EC) 9/13/2013 11:14:46 AM    More...
1234